Amgen third quarter sales rise 8%, led by cholesterol, cancer drugs

What happened

Amgen said third-quarter sales rose 8%, led by demand for cholesterol drug Repatha and newer medicines Imdelltra and Uplizna. Adjusted earnings increased 14% to $6.45 per share, while revenue reached $10.4 billion. The company raised its full-year outlook for adjusted earnings and revenue.

Confirmed

Global impact / market context

Higher sales and an increased outlook suggest stronger expected revenue and profit, which can support investor expectations for Amgen. The growth is linked to existing medicines, while MariTide remains experimental, so it has not yet added sales and its commercial value is uncertain.

Analyst inference

The article reports quarterly revenue above the average analyst estimate and adjusted earnings above expectations, alongside a higher full-year outlook. It also says initial results from MariTide’s Phase 3 trials, late-stage tests in people, are not expected until next year.

Confirmed

What to watch

1. Watch whether demand for Repatha, Imdelltra, and Uplizna continues to support sales in coming quarters; the article identifies these medicines as the main growth drivers. Analyst inference
2. Track whether Amgen delivers within its raised full-year outlook of $22.90 to $23.70 adjusted earnings per share and $38.9 billion to $39.7 billion revenue. Confirmed
3. Look for initial results from MariTide’s Phase 3 trials next year; favorable findings could strengthen its prospects, while delays or weak results could limit them. Analyst inference

Evidence

• Original source link unavailable